Pancreatic Cancer Research

ResearcherChina Medical UniversityActive in the last 2 years

Chun‐Mei Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4248-0896; OpenAlex author ID A5101667817. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
13
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 3 papers

Papers 10

  1. Innovative cyclic peptide disrupts IL-17RB-MLK4 interaction for targeted pancreatic cancer therapy. Co-author DOI 10.1016/j.biopha.2025.117892↗
  2. Correction: SEMA7A-mediated juxtacrine stimulation of IGFBP-3 upregulates IL-17RB at pancreatic cancer invasive front. Last author DOI 10.1038/s41417-024-00857-6↗
  3. RRM1 O-GlcNAcylation inhibition suppresses pancreatic cancer via TK1-mediated replication stress. Last author DOI 10.1038/s41417-025-00895-8↗
  4. Exosomal miRNA 16-5p/29a-3p from pancreatic cancer induce adipose atrophy by inhibiting adipogenesis and promoting lipolysis. Last author DOI 10.1016/j.isci.2024.110346↗
  5. SEMA7A-mediated juxtacrine stimulation of IGFBP-3 upregulates IL-17RB at pancreatic cancer invasive front. Last author DOI 10.1038/s41417-024-00849-6↗
  6. Pancreatic cancer-derived small extracellular vesical ezrin activates fibroblasts to exacerbate cancer metastasis through STAT3 and YAP-1 signaling pathways. Co-author DOI 10.1002/1878-0261.13442↗
  7. Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41419-022-05259-w↗
  8. Characterization of initial key steps of IL-17 receptor B oncogenic signaling for targeted therapy of pancreatic cancer. Co-author DOI 10.1126/scitranslmed.abc2823↗
  9. Pancreatic cancer-derived small extracellular vesical Ezrin regulates macrophage polarization and promotes metastasis. Co-author PMID 32064151↗
  10. Cellular 5-hydroxylmethylcytosine content determines tumorigenic potential and prognosis of pancreatic ductal adenocarcinoma. First author PMID 30662811↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sui-Chih Tien · 7 shared papers, 2020–2025 · strength 1.65
  2. Yu‐Ting Chang · 7 shared papers, 2018–2025 · strength 1.17
  3. Ming‐Chu Chang · 6 shared papers, 2018–2025 · strength 1.04
  4. Hsuan‐Yu Peng · 5 shared papers, 2020–2025 · strength 0.99
  5. Wen‐Hwa Lee · 4 shared papers, 2018–2024 · strength 0.64
  6. Y.M. Chen · 4 shared papers, 2018–2025 · strength 0.61
  7. Yu‐Wen Tien · 4 shared papers, 2018–2025 · strength 0.61
  8. Yung‐Ming Jeng · 4 shared papers, 2018–2023 · strength 0.52
  9. Wei‐Chieh Cheng · 1 shared paper, 2025 · strength 0.23
  10. Yu-Huei Liu · 1 shared paper, 2022 · strength 0.22
  11. Lung‐Hung Tsai · 1 shared paper, 2021 · strength 0.11
  12. Heng‐Hsiung Wu · 1 shared paper, 2021 · strength 0.11
  13. Chia‐Ning Shen · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.